RIMA: a safe concept in the treatment of depression with moclobemide.
Moclobemide--a new, safer antidepressant drug--is described and clinical studies are reviewed. Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A. Unlike classical monoamine oxidase (MAO) inhibitors, moclobemide is devoid of hepatotoxicity and has only a slight potentiating effect on the hypertensive action of tyramine; treatment does not require a tyramine-restricted diet. Studies comparing moclobemide with tricyclic antidepressants (TCAs) indicate that moclobemide is significantly better tolerated than TCAs and slightly less well tolerated than placebo.
Amrein
R
R
Department of Clinical Research, Neuropsychiatry, F. Hoffmann La-Roche Ltd., Basel, Switzerland.
Hetzel
W
W
Stabl
M
M
Schmid-Burgk
W
W
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001549:Benzamides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide